Clinical Value of Molecular Genetic Analyzes in Gynecological Malignomas

The aim of the planned research project is to find out the clinical significance of molecular genetic analyzes in gynecological malignomas. In particular, it will be investigated how the knowledge of a molecular-genetic finding affects the therapeutic decision of the physician. Furthermore, genetic changes in the tumor tissue will be compared with the changes in CTCs, DTCs and cfDNA.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gynecologic Cancer

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

University Women's Hospital

Tübingen, 72076, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with a solid tumor disease
The presence of a molecular genetic diagnosis of the tumor tissue from practice for human genetics
Age > 18 years
informed consent

Exclusion criteria

life expectancy <12 months or worse general condition (Karnofsky <70)

Treatment and study plan

molecular genetic analyses

Diagnostic Test

molecular genetic analyses

Primary outcomes

Influence of molecular genetic findings to the therapy decision

Time frame: 3years

It will be analyzed if the physicians selection of a therapy is influenced by a present molecular genetic finding. Therapy recommondation based on molecular genetic analysis will be compared with the acutal therapy decision.

Sponsors and collaborators

Lead sponsor

University Hospital Tuebingen

Other

Registry information

Acronym: MAGynMA

Important dates

Study start: 2017
Primary completion: 2020
Study completion: 2021
First posted: Jun 21, 2017
Registry last updated: Dec 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed